Swiss Nuclides GmbH is developing novel radionuclides for highly targeted cancer diagnostics together with a radionuclide production network to enhance broad availability and reliability of supply at low manufacturing cost.

Precise diagnosis is key to better patient treatment options and improved patient survival. Radionuclides are becoming game-changers in highly targeted diagnosis and treatment of cancer (radionuclide theranostics) in which a pharmaceutically active molecule is first labelled with a diagnostic isotope and later with a therapeutic isotope of the same element.

Copyright © 2019 Swiss Nuclides